



MAYNE PHARMA ANNOUNCES ISSUANCE OF ADDITIONAL US PATENT FOR NEXTSTELLIS®

6 November 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Estetra SRL, a subsidiary of Mithra Pharmaceuticals SA, licensor of NEXTSTELLIS® contraceptive, has received a notice of issue for a new patent granted by the United States Patent and Trademark Office. The allowed claims provide additional patent protection to the NEXTSTELLIS® formulation.

US Patent No. 11,793,760, with an expiration date of 2036, covers the pharmaceutical composition, thereby providing further protection to the NEXTSTELLIS® oral dosage unit. The patent is a continuation of US Patent No. 11,147,771.

This patent was listed in the Orange Book on Friday, 3 November 2023. This is an additional Orange Book listed patent that strengthens the NEXTSTELLIS® portfolio.

Mayne Pharma's CEO Mr Shawn Patrick O'Brien said: "This additional patent is meaningful as it provides the Company with an opportunity to extend women's access to this highly effective and unique oral contraceptive. This patent is an important part of our strategy to vigorously protect the commercial success of NEXTSTELLIS®, one of our key growth drivers, and to add to the overall strength of our patent portfolio in the US."

For further information contact:

Australia:
Craig Haskins
+61 421 029 843

ir@maynepharma.com

USA:
Lisa M. Wilson
+1 917-543-9932

ir@maynepharma.com

Authorised for release to the ASX by the Chair

About NEXTSTELLIS®

Developed by Mithra, NEXTSTELLIS® is a novel, patent-protected combined oral contraceptive pill containing 14.2 mg estetrol (E4) and 3 mg drospirenone (DRSP). E4 is a naturally produced estrogen during pregnancy that's derived from a plant source in NEXTSTELLIS® tablets. In two phase 3 clinical studies conducted in 3,632 women, NEXTSTELLIS® was shown to be both safe and effective and met its primary endpoint of pregnancy prevention. It also delivered positive results on a variety of secondary endpoints that demonstrated a predictable bleeding pattern with good safety and tolerability, as well as low rates of adverse reactions.



ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

NEXTSTELLIS® is a registered trademark of Estetra SRL, a Mithra Pharmaceuticals company.